ALK 1 Recombinant Protein Cat. No.: 96-022

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Human
SOURCE SPECIES:HEK293 cells
SEQUENCE:Asp 22 - Gln 118
FUSION TAG:His Tag
TESTED APPLICATIONS:WB
APPLICATIONS:This recombinant protein can be used for WB. For research use only.
psi-iconProperties
PURITY:>97% as determined by SDS-PAGE.
PREDICTED MOLECULAR WEIGHT:12.3 kDa
PHYSICAL STATE:Lyophilized
BUFFER:PBS, pH7.4
STORAGE CONDITIONS:Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
psi-iconAdditional Info
ALTERNATE NAMES:ACVRL1, ACVRLK1, ALK-1, HHT, HHT2, ORW2, SKR3, TSR-I
ACCESSION NO.:NP_000011.2
OFFICIAL SYMBOL:ACVRL1
GENE ID:94
psi-iconBackground and References
BACKGROUND:Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.
REFERENCES:1) Ten Dijke P, Ichijo H, et al.,1993, Oncogene 8 (10): 2879–87.
2) Johnson DW, Berg JN, et al., 1996, Nat Genet 13 (2): 189–95.
3) Lawlor MW, Read BP, et al., 2011, Am J Pathol. 178(2):784-93.
4) Mitchell D,et al., 2010, Mol Cancer Ther.. 9(2):379-88.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.